Brief: NetraMark's AI-Based Technology Identifies Significant Drivers Of Efficacy And Placebo
Feb 26 (Reuters) - NetraMark Holdings Inc AIAI.CD :
* NETRAMARK'S AI-BASED TECHNOLOGY IDENTIFIES SIGNIFICANT
DRIVERS
OF EFFICACY AND PLACEBO RESPONSES AND HAS POTENTIAL TO IMPROVE
SUCCESS RATES FOR CLINICAL TRIALS OF PSYCHIATRIC MEDICATIONS
Source text for Eikon: ID:nCNWBxDZPa
Further company coverage: AIAI.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NetraMark Holdings
See all newsBrief: Netramark Announces Uplisting To Toronto Stock Exchange
Brief: Netramark Signs Four New Contracts With A Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights
Brief: Asklepion Pharmaceuticals Signs Contract To Utilize Netramark Technology In Phase III Pediatric Cardiac Study
Brief: NetraMark Holdings Signs Contract With AlgoTx To Enhance Clinical Trial Design For ATX01
Brief: Netramark And Worldwide Clinical Trials Announce Agreement To Transform Clinical Trial Design With Ai-Powered Precision